Kiadis Pharma N.V. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,484.00
5,732.00
28,666.00
14,559.00
29,906.00
60,314
Total Accounts Receivable
49.00
138.00
145.00
230.00
351.00
729
Other Current Assets
-
-
-
-
231.00
-
Total Current Assets
6,533.00
5,870.00
28,811.00
14,789.00
30,488.00
61,043
Net Property, Plant & Equipment
280.00
413.00
333.00
536.00
602.00
7,720
Intangible Assets
13,148.00
13,687.00
12,714.00
13,540.00
12,830.00
12,368
Other Assets
227.00
242.00
418.00
351.00
767.00
1,413
Total Assets
20,188.00
20,212.00
42,276.00
29,216.00
44,687.00
82,544
ST Debt & Current Portion LT Debt
384.00
7,129.00
1,166.00
1,555.00
1,789.00
Accounts Payable
182.00
396.00
596.00
1,268.00
1,366.00
Income Tax Payable
44.00
-
-
-
235.00
Other Current Liabilities
1,009.00
1,202.00
1,151.00
1,347.00
1,854.00
Total Current Liabilities
1,619.00
8,727.00
2,913.00
4,170.00
5,244.00
Long-Term Debt
10,021.00
5,090.00
13,713.00
15,605.00
21,599.00
Provision for Risks & Charges
-
-
-
-
540.00
Other Liabilities
3,189.00
3,730.00
-
-
1,445.00
Total Liabilities
14,829.00
17,547.00
16,626.00
19,775.00
28,828.00
Common Equity (Total)
5,359.00
2,665.00
25,650.00
9,441.00
15,859.00
Total Shareholders' Equity
5,359.00
2,665.00
25,650.00
9,441.00
15,859.00
Total Equity
5,359.00
2,665.00
25,650.00
9,441.00
15,859.00
Liabilities & Shareholders' Equity
20,188.00
20,212.00
42,276.00
29,216.00
44,687.00

About Kiadis Pharma

View Profile
Address
Paasheuvelweg 25
Amsterdam Noord-Holland 1105 BP
Netherlands
Employees -
Website http://www.kiadis.com
Updated 07/08/2019
Kiadis Pharma NV is a clinical stage biopharmaceutical company. It engages in the research, development, and future commercialization of cell-based immunotherapy products for treatment of blood cancers and inherited blood disorders. The company provide the products for Allodepleted T-cell ImmunotheRapeutics that are based on its theralux platform.